NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Active Not RecruitingPhase 2

Sponsor: The Netherlands Cancer Institute

Conditions: Rectal Cancer

Interventions: Atezolizumab, Bevacizumab

Countries: Netherlands

In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* signed informed consent
* patients age 18 years and older
* histologically confirmed adenocarcinoma of the rectum
* intermediate risk rectal cancer or low risk distal rectal cancer

Exclusion Criteria:

* evidence of metastatic disease
* prior radiation therapy for disease under study
* prior treatment with CD137 agonists or immune checkpoint blockade therapies
* current or recent use of acetylsalicylic acid
* history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding
* significant auto-immune disease

Locations (1)

Amsterdam, North Holland, Netherlands